Presentation (CTI)

OBJECTIVES: Joint Clinical Assessments (JCAs) are meant to evaluate one product, not make rules — yet the first cases are watched by everyone planning the next. This analysis examined whether the first orphan oncology JCA (tovorafenib for paediatric low-grade glioma) is functioning as a de facto standard-setting instrument.
METHODS: A governance analysis of the published JCA report identified the methodological positions it articulated — on indirect comparisons, outcome selection, residual confounding, effective sample size, missing prognostic variables, and transparency — and assessed their likely influence on future evidence-generation strategy under Regulation (EU) 2021/2282.
RESULTS: Although formally confined to a single product, the report takes consequential positions that developers, consultants, national bodies, and Joint Scientific Consultation participants will read as signals. Three stood out. Comparability mattered more than analytical sophistication: advanced statistics did not compensate for weak comparators or misaligned populations. Data not collected during development — missing prognostic variables and effect modifiers — became primary drivers of uncertainty rather than secondary concerns. Reproducibility and traceability were treated as central to credibility. In a young framework, such practical precedent can become as influential as formal guidance, contributing to an emerging common evidence culture. The risk is that precedent accumulates case-by-case, without the transparency and deliberation that formal standard-setting would demand.
CONCLUSIONS: Early JCAs are writing the rules by example. If first cases set durable expectations, the methodological reasoning behind their conclusions should be published and debated as standards — not left implicit in single-product reports.